Airway inflammation during late asthmatic reactions induced by toluene diisocyanate. 1991

L M Fabbri, and P Maestrelli, and M Saetta, and C E Mapp
Interuniversity Center on Cellular and Molecular Mechanisms of Lung Injury, University of Brescia, Italy.

To determine the importance of airway inflammation for the development of late asthmatic reactions, we examined sensitized subjects during late asthmatic reactions induced by exposure to toluene diisocyanate (TDI) in the laboratory. Late asthmatic reactions are associated with a transient increase of bronchial responsiveness and, at the same time, with an increase of neutrophils followed by eosinophils, and of LTB4 and albumin in bronchoalveolar lavage fluid. Late asthmatic reactions, increased bronchial responsiveness, and increase of neutrophils, eosinophils, LTB4, and albumin concentration in bronchoalveolar lavage induced by exposure to TDI are all prevented by pretreatment with prednisone but not with the nonsteroidal anti-inflammatory agent indomethacin. Aerosolized steroids (beclomethasone and dexamethasone isonicotinate) completely inhibit late asthmatic reactions induced by TDI, whereas theophylline has a partial, and verapamil, ketotifen, and cromolyn have no protective effect. These results suggest that late asthmatic reactions induced by TDI may be caused by airway inflammation, and that anti-inflammatory steroids should be recommended in the prophylaxis of TDI asthma.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D001980 Bronchi The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI. Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D014051 Toluene 2,4-Diisocyanate Skin irritant and allergen used in the manufacture of polyurethane foams and other elastomers. Diisocyanatotoluene,Tolylene Diisocyanate,2,4-Toluenediisocyanate,Toluene Diisocyanate,2,4 Toluenediisocyanate,2,4-Diisocyanate, Toluene,Diisocyanate, Toluene,Diisocyanate, Tolylene,Toluene 2,4 Diisocyanate
D016084 Bronchoconstriction Narrowing of the caliber of the BRONCHI, physiologically or as a result of pharmacological intervention. Bronchial Constriction,Bronchial Constrictions,Bronchoconstrictions,Constriction, Bronchial,Constrictions, Bronchial

Related Publications

L M Fabbri, and P Maestrelli, and M Saetta, and C E Mapp
July 1987, The American review of respiratory disease,
L M Fabbri, and P Maestrelli, and M Saetta, and C E Mapp
September 1987, The Journal of allergy and clinical immunology,
L M Fabbri, and P Maestrelli, and M Saetta, and C E Mapp
January 1987, Advances in prostaglandin, thromboxane, and leukotriene research,
L M Fabbri, and P Maestrelli, and M Saetta, and C E Mapp
January 1991, Respiration; international review of thoracic diseases,
L M Fabbri, and P Maestrelli, and M Saetta, and C E Mapp
April 1990, Journal of applied physiology (Bethesda, Md. : 1985),
L M Fabbri, and P Maestrelli, and M Saetta, and C E Mapp
May 1992, European journal of pharmacology,
L M Fabbri, and P Maestrelli, and M Saetta, and C E Mapp
October 1986, European journal of respiratory diseases,
L M Fabbri, and P Maestrelli, and M Saetta, and C E Mapp
December 1987, The American review of respiratory disease,
Copied contents to your clipboard!